Mga Batayang Estadistika
| LEI | 529900ER63TFLEIJV631 |
| CIK | 863894 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Veru Inc.
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
| August 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 26, 2025 VERU INC. (Exact name of registrant as specified in its charter) Wisconsin 1-13602 39-1144397 (State or other jurisdiction of incorporation) (Commission File Number) ( |
|
| August 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 1-1360 |
|
| August 12, 2025 |
Articles of Amendment to Amended and Restated Articles of Incorporation of Veru Inc. Exhibit 3.1 ARTICLES OF AMENDMENT TO THE AMENDED AND RESTATED ARTICLES OF INCORPORATION OF VERU INC. 1. The corporate name is Veru Inc. (the "Corporation"), a corporation organized and existing under and by virtue of the Wisconsin Business Corporation Law. 2. The amendment adopted relates to Article V of the Amended and Restated Articles of Incorporation of the Corporation. Article V is amended to |
|
| August 12, 2025 |
Limited Waiver, dated as of June 30, 2025, between the Company and Onconetix, Inc. * Exhibit 10.1 WAIVER This LIMITED WAIVER, dated as of June 30, 2025 (“Limited Waiver”), is made by ONCONETIX, INC (the “Company”) and VERU INC. (the “Holder”). WHEREAS, reference is hereby made to a certain Promissory Note, dated as of April 19, 2023, and which was originally due on April 19, 2024 (the “April 2024 Promissory Note”); WHEREAS, reference is hereby made to a certain Promissory Note, da |
|
| August 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2025 VERU INC. (Exact name of registrant as specified in its charter) Wisconsin 1-13602 39-1144397 (State or other jurisdiction of incorporation) (Commission File Number) (I |
|
| August 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 12, 2025 VERU INC. (Exact name of registrant as specified in its charter) Wisconsin 1-13602 39-1144397 (State or other jurisdiction of incorporation) (Commission File Number) ( |
|
| August 12, 2025 |
EX-99.1 Exhibit 99.1 Investor and Media Contact: Samuel Fisch Executive Director, Investor Relations and Corporate Communications Email: [email protected] Veru Reports Fiscal 2025 Third Quarter Financial Results and Clinical Program Progress —Company reported positive efficacy and safety data from Phase 2b QUALITY study showing enobosarm added to semaglutide led to preservation of muscle |
|
| August 12, 2025 |
Veru Announces Reverse Stock Split Exhibit 99.1 Investor and Media Contact: Samuel Fisch Executive Director, Investor Relations and Corporate Communications Email: [email protected] Veru Announces Reverse Stock Split MIAMI, FL – August 6, 2025 – Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory diseases |
|
| July 25, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 25, 2025 VERU INC. (Exact name of registrant as specified in its charter) Wisconsin 1-13602 39-1144397 (State or other jurisdiction of incorporation) (Commission File Number) (IR |
|
| July 15, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for use of the Commission only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| June 10, 2025 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Prox |
|
| June 10, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Conf |
|
| May 9, 2025 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy |
|
| May 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 8, 2025 VERU INC. (Exact name of registrant as specified in its charter) Wisconsin 1-13602 39-1144397 (State or other jurisdiction of incorporation) (Commission File Number) (IRS |
|
| May 8, 2025 |
Limited Waiver, dated as of March 31, 2025, between the Company and Onconetix, Inc. * Exhibit 10.1 WAIVER This LIMITED WAIVER, dated as of March 31, 2025 (“Limited Waiver”), is made by ONCONETIX, INC (the “Company”) and VERU INC. (the “Holder”). WHEREAS, reference is hereby made to a certain Promissory Note, dated as of April 19, 2023, and which was originally due on April 19, 2024 (the “April 2024 Promissory Note”); WHEREAS, on April 24, 2024, the Borrower and Holder entered into |
|
| May 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 1-136 |
|
| May 8, 2025 |
Exhibit 99.1 Investor and Media Contact: Samuel Fisch Executive Director, Investor Relations and Corporate Communications Email: [email protected] Veru Reports Fiscal 2025 Second Quarter Financial Results and Clinical Program Progress —Unblinded safety data from Phase 2b QUALITY study expected in the second quarter of calendar 2025 — —Topline efficacy and safety data for Phase 2b extensi |
|
| May 8, 2025 |
Limited Waiver, dated as of April 23, 2025, between the Company and Onconetix, Inc. * Exhibit 10.2 WAIVER This LIMITED WAIVER, dated as of April 23, 2025 (“Limited Waiver”), is made by ONCONETIX, INC (the “Company”) and VERU INC. (the “Holder”). WHEREAS, reference is hereby made to a certain Promissory Note, dated as of April 19, 2023, and which was originally due on April 19, 2024 (the “April 2024 Promissory Note”); WHEREAS, on April 24, 2024, the Borrower and Holder entered into |
|
| March 14, 2025 |
Veru Inc. 2018 Equity Incentive Plan (as amended and restated effective March 13, 2025). Exhibit 10.1 VERU INC. 2018 EQUITY INCENTIVE PLAN (as amended and restated effective March 13, 2025) VERU INC. 2018 EQUITY INCENTIVE PLAN 1. Purpose 1 2. Definitions 1 3. Administration 6 4. Shares Subject to Plan 7 5. Eligibility; Per‑Participant Limitations 8 6. Specific Terms of Awards 8 7. Certain Provisions Applicable to Awards 14 8. Change of Control 16 9. General Provisions 19 i VERU INC. 2 |
|
| March 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 13, 2025 VERU INC. (Exact name of registrant as specified in its charter) Wisconsin 1-13602 39-1144397 (State or other jurisdiction of incorporation) (Commission File Number) (I |
|
| February 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 27, 2025 VERU INC. (Exact name of registrant as specified in its charter) Wisconsin 1-13602 39-1144397 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| February 13, 2025 |
EX-99.1 Exhibit 99.1 Investor and Media Contact: Samuel Fisch Executive Director, Investor Relations and Corporate Communications Email: [email protected] Veru Reports Fiscal 2025 First Quarter Financial Results and Clinical Program Progress —Company reported positive Phase 2b QUALITY study topline results for enobosarm + semaglutide (Wegovy®) with study meeting prespecified primary endp |
|
| February 13, 2025 |
Exhibit 10.1 WAIVER AND AMENDMENT NO. 1 TO FORBEARANCE AGREEMENT This LIMITED WAIVER AND AMENDMENT NO. 1, dated as of November 26, 2024 (“Limited Waiver”), is made by ONCONETIX, INC (the “Company”) and VERU INC. (the “Holder”). WHEREAS, reference is hereby made to a certain Promissory Note, dated as of April 19, 2023, and which was originally due on April 19, 2024 (the “April 2024 Promissory Note” |
|
| February 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 1- |
|
| February 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 13, 2025 VERU INC. (Exact name of registrant as specified in its charter) Wisconsin 1-13602 39-1144397 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| January 28, 2025 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy |
|
| January 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Conf |
|
| January 3, 2025 |
UNAUDITED PRO FORMA CONSOLIDATED FINANCIAL STATEMENTS Exhibit 99.2 UNAUDITED PRO FORMA CONSOLIDATED FINANCIAL STATEMENTS On December 30, 2024, Veru Inc. (the “Company”) and The Female Health Company Limited, a wholly owned subsidiary of the Company (“FHC Limited” and, collectively with the Company, the “Sellers”) entered into a Stock and Asset Purchase Agreement (the "Purchase Agreement") with Clear Future, Inc. (the "Purchaser"). Pursuant to, and su |
|
| January 3, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December30, 2024 VERU INC. (Exact name of registrant as specified in its charter) Wisconsin 1-13602 39-1144397 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| January 3, 2025 |
Veru Announces the Sale of the FC2 Female Condom® (Internal Condom) Business Exhibit 99.1 Investor and Media Contact: Samuel Fisch Executive Director, Investor Relations and Corporate Communications Email: [email protected] Veru Announces the Sale of the FC2 Female Condom® (Internal Condom) Business MIAMI, FL – December 31, 2024 – Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving mu |
|
| January 3, 2025 |
Exhibit 10.1 STOCK AND ASSET PURCHASE AGREEMENT by and among VERU INC., THE FEMALE HEALTH COMPANY LIMITED and CLEAR FUTURE, INC. Dated effective as of December 30, 2024 TABLE OF CONTENTS Page 1. Defined Terms; Construction 1 1.01. Defined Terms 1 1.02. Construction 16 2. Purchase and Sale; Closing 17 2.01. Purchase and Sale of Stock 17 2.02. Purchase and Sale of Assets 17 2.03. Liabilities 21 2.04 |
|
| December 16, 2024 |
Subsidiaries of Registrant. ** Exhibit 21 Subsidiaries of Veru Inc. (1) The subsidiaries of Veru Inc. are as follows: Name Jurisdiction of Organization Aspen Park Pharmaceuticals, Inc. Delaware Badger Acquisition Sub, Inc. Delaware The Female Health Company Limited United Kingdom The Female Health Company (UK) Plc. United Kingdom The Female Health Company (M) SDN.BHD Malaysia Veru International Holdco Inc. Delaware Veru |
|
| December 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| December 16, 2024 |
Veru Inc. Insider Trading Policy. ** Exhibit 19 Insider Trading Policy Purpose The Board of Directors of Veru Inc. (the "Company") has adopted this Insider Trading Policy (“Policy”) with respect to transactions in the Company's securities, as well as the securities of publicly traded companies with whom the Company has a business relationship. This Policy is designed to prevent insider trading or allegations of insider trading, and t |
|
| December 12, 2024 |
As filed with the Securities and Exchange Commission on December 12, 2024. As filed with the Securities and Exchange Commission on December 12, 2024. Registration Statement No. 333-271891 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 to FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 VERU INC. (Exact Name of Registrant as Specified in Its Charter) Wisconsin 39-1144397 (State or Other Jurisdiction o |
|
| November 12, 2024 |
VERU / Veru Inc. / Adage Capital Management, L.P. Passive Investment SC 13G/A 1 p24-3043sc13ga.htm SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)*, ** Veru Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 92536C103 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to desig |
|
| November 4, 2024 |
VERU / Veru Inc. / MILLENNIUM MANAGEMENT LLC Passive Investment SC 13G/A 1 VERUSC13GA1.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (AMENDMENT NO. 1) VERU INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.01 PER SHARE (Title of Class of Securities) 92536C103 (CUSIP Number) SEPTEMBER 30, 2024 (Date of event which requires filing of this statement) Check the appropriate box to d |
|
| September 20, 2024 |
Exhibit 10.1 AMENDED AND RESTATED FORBEARANCE AGREEMENT AND AMENDMENT TO SEPTEMBER 2024 NOTE THIS AMENDED AND RESTATED FORBEARANCE AGREEMENT AND AMENDMENT TO SEPTEMBER 2024 NOTE (this “Agreement”) is entered into as of this 19th day of SEPTEMBER, 2024 (the “Effective Date”), by and among Onconetix, Inc., a Delaware corporation (“Borrower”), and Veru Inc., a Wisconsin corporation (“Holder”). Capita |
|
| September 20, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 19, 2024 VERU INC. (Exact name of registrant as specified in its charter) Wisconsin 1-13602 39-1144397 (State or other jurisdiction of incorporation) (Commission File Number |
|
| August 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 29, 2024 VERU INC. (Exact name of registrant as specified in its charter) Wisconsin 1-13602 39-1144397 (State or other jurisdiction of incorporation) (Commission File Number) ( |
|
| August 23, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 19, 2024 VERU INC. (Exact name of registrant as specified in its charter) Wisconsin 1-13602 39-1144397 (State or other jurisdiction of incorporation) (Commission File Number) ( |
|
| August 8, 2024 |
EX-99.1 Exhibit 99.1 Investor and Media Contact: Samuel Fisch Executive Director, Investor Relations and Corporate Communications Email: [email protected] Veru Reaches Full Enrollment for Phase 2b QUALITY Clinical Study of Enobosarm for Obesity and Reports Fiscal 2024 Third Quarter Financial Results —Phase 2b QUALITY study of enobosarm in combination with semaglutide (Wegovy®*) exceeds t |
|
| August 8, 2024 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2024 VERU INC. (Exact name of registrant as specified in its charter) Wisconsin 1-13602 39-1144397 (State or other jurisdiction of incorporation) (Commission File Number) (I |
|
| August 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 1-1360 |
|
| August 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 1, 2024 VERU INC. (Exact name of registrant as specified in its charter) Wisconsin 1-13602 39-1144397 (State or other jurisdiction of incorporation) (Commission File Number) (I |
|
| July 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 27, 2024 VERU INC. (Exact name of registrant as specified in its charter) Wisconsin 1-13602 39-1144397 (State or other jurisdiction of incorporation) (Commission File Number) (IR |
|
| June 21, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 18, 2024 VERU INC. (Exact name of registrant as specified in its charter) Wisconsin 1-13602 39-1144397 (State or other jurisdiction of incorporation) (Commission File Number) (IR |
|
| June 20, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for use of the Commission only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| June 18, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for use of the Commission only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| May 22, 2024 |
Letter of RSM US LLP dated May 22, 2024 concerning change in the registrant’s certifying accountant. Exhibit 16.1 May 22, 2024 Securities and Exchange Commission Washington, D.C. 20549 Commissioners: We have read Veru Inc.’s statements included under Item 4.01(a) of its Form 8-K filed on May 22, 2024 and we agree with such statements concerning our firm. RSM US LLP is the U.S. member firm of RSM International, a global network of independent audit, tax, and consulting firms. Visit rsmus.com/about |
|
| May 22, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 16, 2024 VERU INC. (Exact name of registrant as specified in its charter) Wisconsin 1-13602 39-1144397 (State or other jurisdiction of incorporation) (Commission File Number) (IRS |
|
| May 9, 2024 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. 1) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Prox |
|
| May 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. 1) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confi |
|
| May 8, 2024 |
EX-99.1 Exhibit 99.1 Investor and Media Contact: Samuel Fisch Executive Director, Investor Relations and Corporate Communications Email: [email protected] Veru Reports Fiscal 2024 Second Quarter Financial Results and Progress of its Enobosarm High Quality Weight Loss Clinical Program —Phase 2b clinical study of enobosarm in combination with semaglutide (Wegovy®*) for high quality weight |
|
| May 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 1-13602 Veru Inc. (Exac |
|
| May 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 8, 2024 VERU INC. (Exact name of registrant as specified in its charter) Wisconsin 1-13602 39-1144397 (State or other jurisdiction of incorporation) (Commission File Number) (IRS |
|
| April 26, 2024 |
Exhibit 10.1 FORBEARANCE AGREEMENT THIS FORBEARANCE AGREEMENT (this “Agreement”) is entered into as of this 24th day of April, 2024 (the “Effective Date”), by and among Onconetix, Inc., a Delaware corporation (“Borrower”), and Veru Inc., a Wisconsin corporation (“Holder”). Capitalized terms not otherwise defined herein shall have the meanings given to such terms in the Promissory Notes (as defined |
|
| April 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 24, 2024 VERU INC. (Exact name of registrant as specified in its charter) Wisconsin 1-13602 39-1144397 (State or other jurisdiction of incorporation) (Commission File Number) (I |
|
| April 25, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 23, 2024 VERU INC. (Exact name of registrant as specified in its charter) Wisconsin 1-13602 39-1144397 (State or other jurisdiction of incorporation) (Commission File Number) (I |
|
| April 24, 2024 |
VERU / Veru Inc. / MILLENNIUM MANAGEMENT LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 VERU INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.01 PER SHARE (Title of Class of Securities) 92536C103 (CUSIP Number) APRIL 18, 2024 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule pursuant to which this Schedule |
|
| April 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2023 ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 1-13602 Veru Inc. (E |
|
| April 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for use of the Commission only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| April 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) (Mark One) þ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended September 30, 2023 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 1-1360 |
|
| March 22, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☐ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| February 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 21, 2024 VERU INC. (Exact name of registrant as specified in its charter) Wisconsin 1-13602 39-1144397 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| February 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 15, 2024 VERU INC. (Exact name of registrant as specified in its charter) Wisconsin 1-13602 39-1144397 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| February 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR For Period Ended: December 31, 2023. |
|
| February 14, 2024 |
EX-99.1 2 d629938dex991.htm EX-99.1 EXHIBIT 1 AGREEMENT The persons below hereby agree that the Schedule 13G to which this agreement is attached as an exhibit, as well as all future amendments to such Schedule 13G, shall be filed on behalf of each of them. This agreement is intended to satisfy the requirements of Rule 13d-1(k)(1)(iii) under the Securities Exchange Act of 1934. Date: February 14, 2 |
|
| February 14, 2024 |
VERU / Veru Inc. / PERCEPTIVE ADVISORS LLC - SC 13G/A Passive Investment SC 13G/A 1 d629938dsc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Veru Inc. (Name of Issuer) Common Stock, $0.01 par value per share (Title of Class of Securities) 92536C 103 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appro |
|
| February 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 8, 2024 VERU INC. (Exact name of registrant as specified in its charter) Wisconsin 1-13602 39-1144397 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| February 8, 2024 |
Exhibit 99.1 Investor and Media Contact: Samuel Fisch Executive Director, Investor Relations and Corporate Communications Email: [email protected] Veru Reports Fiscal 2024 First Quarter Financial Highlights —Company receives FDA IND clearance for the development of enobosarm in combination with GLP-1 drugs for potentially higher quality weight loss than has been shown with GLP-1 drug alo |
|
| February 6, 2024 |
VERU / Veru Inc. / FROST PHILLIP MD ET AL - SC 13G/A Passive Investment SC 13G/A 1 tm245362d2sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 2) Veru Inc. (Name of Issuer) Common stock, par value $0.01 per share (“Common Stock”) (Title of Class of Securities) 92536C103 (CUSIP Number) January 16, 2024 (Date of Event Which Requires Filing of this Statement) |
|
| February 6, 2024 |
EX-1 2 tm245362d2ex1.htm EX-99.1 Exhibit 1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the undersigned agree to the joint filing on behalf of each of them of a Statement on Schedule 13G (including any and all amendments thereto) with respect to the Common Stock, $0.01 par value, of Veru Inc., a Wisconsin corporation, and further ag |
|
| January 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 25, 2024 VERU INC. (Exact name of registrant as specified in its charter) Wisconsin 1-13602 39-1144397 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| January 26, 2024 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the registrant ☒ Filed by a party other than the registrant ☐ Check the appropriate box: ☐ Preliminary proxy statement ☐ Con |
|
| January 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the registrant ☒ Filed by a party other than the registrant ☐ Check the appropriate box: ☐ Preliminary proxy statement ☐ Confidential, for use o |
|
| December 26, 2023 |
VERU / Veru Inc. / ADAGE CAPITAL PARTNERS GP, L.L.C. - VERU INC. Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Veru Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 92536C103 (CUSIP Number) December 14, 2023 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule pursuant to which this S |
|
| December 18, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 14, 2023 VERU INC. (Exact name of registrant as specified in its charter) Wisconsin 1-13602 39-1144397 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| December 18, 2023 |
Exhibit 1.1 VERU INC. 45,833,333 Shares of Common Stock (par value $0.01 per share) Underwriting Agreement December 14, 2023 Raymond James & Associates, Inc. Oppenheimer & Co. Inc. As Representatives of the Several Underwriters c/o Raymond James & Associates, Inc. 880 Carillon Parkway, Tower 3 St. Petersburg, FL 33716 c/o Oppenheimer & Co. Inc. 85 Broad Street, 23rd Floor New York, NY 10004 Ladies |
|
| December 18, 2023 |
Veru Announces Pricing of Public Offering of Common Stock Exhibit 99.2 Veru Announces Pricing of Public Offering of Common Stock MIAMI – December 14, 2023 –– Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing novel medicines for the treatment of metabolic diseases, oncology and viral-induced acute respiratory distress syndrome, announced today the pricing of an underwritten public offering of 45,833,333 shares |
|
| December 18, 2023 |
Veru Announces Proposed Public Offering of Common Stock Exhibit 99.1 Veru Announces Proposed Public Offering of Common Stock MIAMI, FL – December 13, 2023 – Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing novel medicines for the treatment of metabolic diseases, oncology and viral-induced acute respiratory distress syndrome, announced today that it has commenced an underwritten public offering of shares of |
|
| December 15, 2023 |
45,833,333 Shares VERU INC. Common Stock 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-270606 PROSPECTUS SUPPLEMENT (To Prospectus dated April 14, 2023) 45,833,333 Shares VERU INC. Common Stock We are offering 45,833,333 shares of our common stock. Our common stock is listed on the Nasdaq Capital Market under the symbol “VERU.” On December 13, 2023, the last reported sale price of our common stock was $0.8 |
|
| December 13, 2023 |
EX-99.1 Forward looking statements and safe harbor The statements in this document that are not historical facts are “forward-looking statements” as that term is defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this document include statements regarding: the planned design, enrollment, timing, commencement, interim and full data readout timing, scope, |
|
| December 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 13, 2023 VERU INC. (Exact name of registrant as specified in its charter) Wisconsin 1-13602 39-1144397 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| December 13, 2023 |
Exhibit 10.1 December 13, 2023 Lincoln Park Capital, LLC 440 North Wells, Suite 410 Chicago, IL 60654 Attention: Josh Scheinfeld/Jonathan Cope Gentlemen, Reference is made to (i) that certain Purchase Agreement (the “Agreement”), dated as of May 2, 2023, by and between Veru Inc., a Wisconsin corporation (the “Company”), and Lincoln Park Fund, LLC, an Illinois limited liability company (the “Invest |
|
| December 13, 2023 |
Filed Pursuant to Rule 424(b)(5) Registration No. 333-270606 PROSPECTUS SUPPLEMENT NO. 2 (To Prospectus dated April 14, 2023) Veru Inc. Up to $50,000,000 of Shares of Common Stock and Up to $2,000,000 of Shares of Common Stock as Commitment Shares This prospectus supplement No. 2 dated December 13, 2023 (this “Prospectus Supplement”), supplements and amends our base prospectus dated April 14, 2023 |
|
| December 13, 2023 |
Subject to completion, dated December 13, 2023 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-270606 The information in this preliminary prospectus supplement is not complete and may be changed. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell these securities and are not soliciting an offer to buy these securities in any jurisdiction where the offer or sale is not permitt |
|
| December 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) þ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended September 30, 2023 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 1-13602 Veru Inc. (Name of |
|
| December 8, 2023 |
Exhibit 21 Subsidiaries of Veru Inc. (1) The subsidiaries of Veru Inc. are as follows: Name Jurisdiction of Organization Aspen Park Pharmaceuticals, Inc. Delaware Badger Acquisition Sub, Inc. Delaware The Female Health Company Limited United Kingdom The Female Health Company (UK) Plc. United Kingdom The Female Health Company (M) SDN.BHD Malaysia Veru International Holdco Inc. Delaware Ve |
|
| December 8, 2023 |
Exhibit 97.1 VERU INC. CLAWBACK POLICY (adopted as of November 30, 2023) Introduction The Board of Directors (the “Board”) of Veru Inc. (the “Company”) believes that it is in the best interests of the Company and its shareholders to create and maintain a culture that emphasizes integrity and accountability and that reinforces the Company's pay-for-performance compensation philosophy. The Board |
|
| December 8, 2023 |
Exhibit 4.3 DESCRIPTION OF CAPITAL STOCK The following is a summary description of the material terms of the common stock and preferred stock of Veru Inc. (the “Company,” “we,” “us” or “our”). It may not contain all the information that is important to you. For additional information, you should look at our amended and restated articles of incorporation, as amended, and our amended and restate |
|
| November 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 10, 2023 VERU INC. (Exact name of registrant as specified in its charter) Wisconsin 1-13602 39-1144397 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| November 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A (Amendment No. 1) (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 1-13 |
|
| October 2, 2023 |
EX-10.1 Exhibit 10.1 AMENDMENT TO ASSET PURCHASE AGREEMENT This Amendment to Asset Purchase Agreement (the “Amendment”) is made effective as of September 29, 2023 by and between Veru Inc., a Wisconsin corporation (the “Seller”), and Blue Water Biotech, Inc., a Delaware corporation (“Buyer”). Seller and Buyer are sometimes referred to herein individually as a “Party” and collectively as the “Partie |
|
| October 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 29, 2023 VERU INC. (Exact name of registrant as specified in its charter) Wisconsin 1-13602 39-1144397 (State or other jurisdiction of incorporation) (Commission File Number |
|
| September 28, 2023 |
VERU / Veru Inc / FROST PHILLIP MD ET AL - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1) Veru Inc. (Name of Issuer) Common stock, par value $0.01 per share (“Common Stock”) (Title of Class of Securities) 92536C103 (CUSIP Number) September 19, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate |
|
| September 28, 2023 |
EX-99.1 2 tm2327096d1ex1.htm EXHIBIT 1 Exhibit 1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the undersigned agree to the joint filing on behalf of each of them of a Statement on Schedule 13G (including any and all amendments thereto) with respect to the Common Stock, $0.01 par value, of Veru Inc., a Wisconsin corporation, and furt |
|
| September 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 11, 2023 VERU INC. (Exact name of registrant as specified in its charter) Wisconsin 1-13602 39-1144397 (State or other jurisdiction of incorporation) (Commission File Number |
|
| August 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 1-13602 Veru Inc. (Exact |
|
| August 10, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 10, 2023 VERU INC. (Exact name of registrant as specified in its charter) Wisconsin 1-13602 39-1144397 (State or other jurisdiction of incorporation) (Commission File Number) ( |
|
| August 10, 2023 |
EX-99.1 Exhibit 99.1 Investor and Media Contact: Samuel Fisch Executive Director, Investor Relations and Corporate Communications Email: [email protected] Veru Reports Fiscal 2023 Third Quarter Financial Results Company receives further regulatory clarity from FDA on Phase 3 ENABLAR-2 study. Potential for enobosarm +/- abemaciclib accelerated approval pathway in metastatic breast cancer, |
|
| July 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 24, 2023 VERU INC. (Exact name of registrant as specified in its charter) Wisconsin 1-13602 39-1144397 (State or other jurisdiction of incorporation) (Commission File Number) (IR |
|
| July 28, 2023 |
EX-3.1 Exhibit 3.1 ARTICLES OF AMENDMENT TO THE AMENDED AND RESTATED ARTICLES OF INCORPORATION OF VERU INC. 1. The name of the Corporation is Veru Inc. 2. The amendment adopted relates to Article V of the Amended and Restated Articles of Incorporation. The first portion of Article V is amended to read as follows: ARTICLE V The aggregate number of shares which the Corporation shall have the authori |
|
| June 12, 2023 |
DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| June 12, 2023 |
DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the registrant ☒ Filed by a party other than the registrant ☐ Check the appropriate box: ☐ Preliminary proxy statement ☐ Confidential, fo |
|
| May 22, 2023 |
VERU INC. 2916 N. Miami Avenue Suite 1000 Miami, Florida 33127 May 22, 2023 Acceleration Request VERU INC. 2916 N. Miami Avenue Suite 1000 Miami, Florida 33127 May 22, 2023 SENT VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 Ladies and Gentlemen: Re: Veru Inc. Registration Statement on Form S-3 (File No. 333-271891) In accordance with Rule 461 under the Securities Act of 1933, as amended, on behalf of V |
|
| May 15, 2023 |
PRE 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| May 12, 2023 |
EX-1.1 Exhibit 1.1 OPEN MARKET SALE AGREEMENTSM May 12, 2023 JEFFERIES LLC 520 Madison Avenue New York, New York 10022 Ladies and Gentlemen: Veru Inc., a Wisconsin corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time through Jefferies LLC, as sales agent and/or principal (the “Agent”), shares of the Company’s common stock, pa |
|
| May 12, 2023 |
Calculation of Filing Fee Table EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Veru Inc. |
|
| May 12, 2023 |
Veru Inc. Up to $75,000,000 Common Stock (Not to exceed 39,609,072 shares) 424B5 Table of Contents Filed pursuant to Rule 424(b)(5) (Registration No. 333-270606) PROSPECTUS SUPPLEMENT (To Prospectus dated April 14, 2023) Veru Inc. Up to $75,000,000 Common Stock (Not to exceed 39,609,072 shares) On May 12, 2023, we entered into an Open Market Sale AgreementSM (the “Sales Agreement”), with Jefferies LLC (“Jefferies” or the “Agent”), relating to the sale of shares of our co |
|
| May 12, 2023 |
Form 424(b)(5) (Form Type) Veru Inc. (Exact Name of Registrant as Specified in its Charter) EX-FILING FEES Exhibit 107 Filing Fee Exhibit Form 424(b)(5) (Form Type) Veru Inc. |
|
| May 12, 2023 |
Powers of Attorney (included on signature page to this Registration Statement). S-3 Table of Contents As filed with the Securities and Exchange Commission on May 12, 2023. |
|
| May 12, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 12, 2023 VERU INC. (Exact name of registrant as specified in its charter) Wisconsin 1-13602 39-1144397 (State or other jurisdiction of incorporation) (Commission File Number) (IRS |
|
| May 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 1-13602 Veru Inc. (Exac |
|
| May 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 11, 2023 VERU INC. (Exact name of registrant as specified in its charter) Wisconsin 1-13602 39-1144397 (State or other jurisdiction of incorporation) (Commission File Number) (IRS |
|
| May 11, 2023 |
EX-99.1 Exhibit 99.1 Investor Contact: Samuel Fisch Executive Director, Investor Relations and Corporate Communications Email: [email protected] Media Contact: Hannah Gendel Manager, Corporate Communications Email: [email protected] Veru Reports Fiscal 2023 Second Quarter Financial Results Agreement reached with FDA on confirmatory Phase 3 clinical trial design for sabizabulin treatme |
|
| May 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 2, 2023 VERU INC. (Exact name of registrant as specified in its charter) Wisconsin 1-13602 39-1144397 (State or other jurisdiction of incorporation) (Commission File Number) (IRS |
|
| May 3, 2023 |
EX-10.2 Exhibit 10.2 REGISTRATION RIGHTS AGREEMENT THIS REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of May 2, 2023, is entered into by and between VERU INC., a Wisconsin corporation (the “Company”), and LINCOLN PARK CAPITAL FUND, LLC, an Illinois limited liability company (together with its permitted assigns, the “Investor”). Capitalized terms used herein and not otherwise defined h |
|
| May 3, 2023 |
Form 424(b)(5) (Form Type) Veru Inc. (Exact Name of Registrant as Specified in its Charter) EX-FILING FEES Exhibit 107 Filing Fee Exhibit Form 424(b)(5) (Form Type) Veru Inc. |
|
| May 3, 2023 |
424B5 Table of Contents Filed pursuant to Rule 424(b)(5) (Registration No. 333-270606) PROSPECTUS SUPPLEMENT (To Prospectus dated April 14, 2023) Veru Inc. Up to $100,000,000 of Shares of Common Stock and Up to $2,000,000 of Shares of Common Stock as Commitment Shares This prospectus supplement relates to the issuance and sale of up to $100,000,000 in shares of our common stock (the “Purchase Shar |
|
| May 3, 2023 |
EX-10.1 Exhibit 10.1 PURCHASE AGREEMENT THIS PURCHASE AGREEMENT (the “Agreement”), dated as of May 2, 2023, is made by and between VERU INC., a Wisconsin corporation (the “Company”), and LINCOLN PARK CAPITAL FUND, LLC, an Illinois limited liability company (the “Investor”). Capitalized terms used herein and not otherwise defined herein are defined in Section 1 hereof. WHEREAS: Subject to the terms |
|
| April 20, 2023 |
EX-10.1 Exhibit 10.1 ASSET PURCHASE AGREEMENT BY AND BETWEEN BLUE WATER VACCINES INC. AND VERU INC. DATED AS OF APRIL 19, 2023 TABLE OF CONTENTS 1. Defined Terms; Construction 1 1.01 Defined Terms 1 1.02 Construction 12 2. Sale of Assets 13 3. Assets Excluded From Transaction 13 4. Excluded Liabilities; Assumption of Liabilities; Non-Assignable Assets 14 4.01 Excluded Liabilities 14 4.0 |
|
| April 20, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 19, 2023 VERU INC. (Exact name of registrant as specified in its charter) Wisconsin 1-13602 39-1144397 (State or other jurisdiction of incorporation) (Commission File Number) (I |
|
| April 19, 2023 |
Exhibit 1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the undersigned agree to the joint filing on behalf of each of them of a Statement on Schedule 13G (including any and all amendments thereto) with respect to the Common Stock, $0. |
|
| April 19, 2023 |
VERU / Veru Inc / FROST PHILLIP MD ET AL - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 Veru Inc. (Name of Issuer) Common stock, par value $0.01 per share (“Common Stock”) (Title of Class of Securities) 92536C103 (CUSIP Number) April 12, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to wh |
|
| April 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 12, 2023 VERU INC. (Exact name of registrant as specified in its charter) Wisconsin 1-13602 39-1144397 (State or other jurisdiction of incorporation) (Commission File Number) (I |
|
| April 13, 2023 |
VERU INC. 2916 N. Miami Avenue Suite 1000 Miami, Florida 33127 April 13, 2023 Acceleration Request VERU INC. 2916 N. Miami Avenue Suite 1000 Miami, Florida 33127 April 13, 2023 SENT VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 Ladies and Gentlemen: Re: Veru Inc. Registration Statement on Form S-3 (File No. 333-270606) In accordance with Rule 461 under the Securities Act of 1933, as amended, on behalf of |
|
| April 13, 2023 |
EX-10.1 Exhibit 10.1 STOCK PURCHASE AGREEMENT This Stock Purchase Agreement (this “Agreement”), is made and entered into as of April 12, 2023, by and between Veru Inc., a Wisconsin corporation (the “Company”), and Frost Gamma Investments Trust (the “Purchaser”). RECITAL The Purchaser wishes to purchase, and the Company wishes to sell, 5,000,000 shares of the Company’s common stock, par value $0.01 |
|
| April 12, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 11, 2023 VERU INC. (Exact name of registrant as specified in its charter) Wisconsin 1-13602 39-1144397 (State or other jurisdiction of incorporation) (Commission File Number) (I |
|
| April 11, 2023 |
As filed with the Securities and Exchange Commission on April 11, 2023. S-3/A Table of Contents As filed with the Securities and Exchange Commission on April 11, 2023. |
|
| March 31, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 28, 2023 VERU INC. (Exact name of registrant as specified in its charter) Wisconsin 1-13602 39-1144397 (State or other jurisdiction of incorporation) (Commission File Number) (I |
|
| March 31, 2023 |
CORRESP Reinhart Boerner Van Deuren s.c. P.O. Box 2965 Milwaukee, WI 53201-2965 1000 North Water Street Suite 1700 Milwaukee, WI 53202 Telephone: Facsimile: 414-298-8097 reinhartlaw.com March 31, 2023 Benjamin G. Lombard Direct Dial: 414-298-8225 [email protected] SENT VIA EDGAR Daniel Crawford United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| March 16, 2023 |
Calculation of Filing Fee Table EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Veru Inc. |
|
| March 16, 2023 |
S-3 Table of Contents As filed with the Securities and Exchange Commission on March 16, 2023. |
|
| March 16, 2023 |
EX-4.11 Exhibit 4.11 VERU INC. and [] as Trustee Guaranteed to the extent set forth therein by the Guarantors named herein. INDENTURE dated as of TABLE OF CONTENTS Page Article 1 DEFINITIONS AND INCORPORATION BY REFERENCE 1 Section 1.01 Certain Definitions 1 Section 1.02 Other Definitions 3 Section 1.03 Incorporation by Reference of Trust Indenture Act 4 Section 1.04 Rules of Construction 4 Articl |
|
| March 14, 2023 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 14, 2023 VERU INC. (Exact name of registrant as specified in its charter) Wisconsin 1-13602 39-1144397 (State or other jurisdiction of incorporation) (Commission File Number) (I |
|
| February 14, 2023 |
EX-99.1 2 d431591dex991.htm EX-99.1 EXHIBIT 1 AGREEMENT The persons below hereby agree that the Schedule 13G to which this agreement is attached as an exhibit, as well as all future amendments to such Schedule 13G, shall be filed on behalf of each of them. This agreement is intended to satisfy the requirements of Rule 13d-1(k)(1)(iii) under the Securities Exchange Act of 1934. Date: February 14, 2 |
|
| February 14, 2023 |
VERU / Veru Inc / PERCEPTIVE ADVISORS LLC - SC 13G Passive Investment SC 13G 1 d431591dsc13g.htm SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Veru Inc. (Name of Issuer) Common Shares, $0.00001 par value per share (Title of Class of Securities) 92536C 103 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropria |
|
| February 14, 2023 |
VERU / Veru Inc / TANG CAPITAL PARTNERS LP - AMENDMENT NO. 1 Passive Investment SC 13G/A 1 veru28231sc13ga1.htm AMENDMENT NO. 1 Securities and Exchange Commission Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Veru, Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 92536C103 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of This Statement) Check the appropriate |
|
| February 9, 2023 |
EX-99.1 Exhibit 99.1 Investor Contact: Samuel Fisch Executive Director, Investor Relations and Corporate Communications Email: [email protected] Media Contact: Hannah Gendel Manager, Corporate Communications Email: [email protected] Veru Reports Fiscal 2023 First Quarter Financial Results Sabizabulin for moderate to severe COVID-19 under review for potential emergency authorization by |
|
| February 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2022 ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 1-13602 Veru Inc. (E |
|
| February 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 9, 2023 VERU INC. (Exact name of registrant as specified in its charter) Wisconsin 1-13602 39-1144397 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| January 27, 2023 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the registrant ☒ Filed by a party other than the registrant ☐ Check the appropriate box: ☐ Preliminary proxy statement ☐ Con |
|
| January 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the registrant ☒ Filed by a party other than the registrant ☐ Check the appropriate box: ☐ Preliminary proxy statement ☐ Confidential, for use o |
|
| December 5, 2022 |
EX-99.1 Exhibit 99.1 Investor Contact: Samuel Fisch Executive Director, Investor Relations and Corporate Communications Email: [email protected] Media Contact: Hannah Gendel Manager, Corporate Communications Email: [email protected] Veru Reports Fiscal 2022 Fourth Quarter and Full Year Financial Results U.S. FDA reviewing EUA application for sabizabulin to treat hospitalized COVID-19 |
|
| December 5, 2022 |
Exhibit 21 ? Subsidiaries of Veru Inc. (1) ? The subsidiaries of Veru Inc. are as follows: ? ? Name Jurisdiction of Organization ? Aspen Park Pharmaceuticals, Inc. Delaware Badger Acquisition Sub, Inc. Delaware The Female Health Company Limited United Kingdom The Female Health Company (UK) Plc. United Kingdom The Female Health Company (M) SDN.BHD Malaysia Veru International Holdco Inc. Delaware Ve |
|
| December 5, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES ?SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended September 30, 2022 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 1-13602 Veru Inc. (Name of |
|
| December 5, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 5, 2022 VERU INC. (Exact name of registrant as specified in its charter) Wisconsin 1-13602 39-1144397 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| December 5, 2022 |
Exhibit 4.3 ? DESCRIPTION OF CAPITAL STOCK ? The following is a summary description of the material terms of the common stock and preferred stock of Veru Inc. (the ?Company,? ?we,? ?us? or ?our?). It may not contain all the information that is important to you. For additional information, you should look at our amended and restated articles of incorporation, as amended, and our amended and restate |
|
| November 14, 2022 |
VERU / Veru Inc / RA CAPITAL MANAGEMENT, L.P. - SC 13G/A Passive Investment SC 13G/A 1 tm2230337d2sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* VERU INC. (Name of Issuer) Common Stock, $0.01 par value per share (Title of Class of Securities) 92536C103 (CUSIP Number) November 14, 2022 (Date of Event Which Requires Filing of this Statement) Check the app |
|
| August 11, 2022 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Veru Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Title of Securities to be Registered Fee Calculation Rule Amount to be Registered Proposed Maximum Aggregate Offering Price Proposed Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common St |
|
| August 11, 2022 |
As filed with the Securities and Exchange Commission on August 11, 2022 As filed with the Securities and Exchange Commission on August 11, 2022 Registration No. |
|
| August 11, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 11, 2022 VERU INC. (Exact name of registrant as specified in its charter) Wisconsin 1-13602 39-1144397 (State or other jurisdiction of incorporation) (Commission File Number) ( |
|
| August 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 1-13602 Veru Inc. (Exact |
|
| August 11, 2022 |
Exhibit 10.1 VERU INC. 2022 EMPLOYMENT INDUCEMENT EQUITY INCENTIVE PLAN ? VERU INC. 2022 EMPLOYMENT INDUCEMENT EQUITY INCENTIVE PLAN ? ? ? Page 1 Purpose 3 2 Definitions 3 3 Administration 8 4 Shares Subject to Plan 9 5 Eligibility; Per?Participant Limitations 10 6 Specific Terms of Awards 11 7 Certain Provisions Applicable to Awards 17 8 Change of Control 19 9 General Provisions 24 ? 2 VERU INC. |
|
| August 11, 2022 |
Exhibit 99.1 Investor and Media Contact: Samuel Fisch Executive Director, Investor Relations and Corporate Communications Email: [email protected] Veru Reports Third Quarter Fiscal 2022 Financial Results; Progresses Sabizabulin Treatment for COVID-19 Towards Regulatory Decisions in Key Territories ?Sabizabulin for COVID-19 Emergency Use Authorization Application Submitted to U.S. FDA in |
|
| June 6, 2022 |
VERU / Veru Inc / TANG CAPITAL PARTNERS LP Passive Investment Securities and Exchange Commission Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| June 6, 2022 |
Exhibit 99.1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1) promulgated under the Securities Exchange Act of 1934, the undersigned agree to the joint filing of a Statement on Schedule 13G (including any and all amendments thereto) with respect to the Common Stock, $0.01 par value per share, of Veru, Inc. and further agree to the filing of this Joint Filing Agreement as an exhibit there |
|
| May 12, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 12, 2022 VERU INC. (Exact name of registrant as specified in its charter) Wisconsin 1-13602 39-1144397 (State or other jurisdiction of incorporation) (Commission File Number) (IRS |
|
| May 12, 2022 |
EX-99.1 Exhibit 99.1 Investor and Media Contact: Samuel Fisch Executive Director, Investor Relations and Corporate Communications Email: [email protected] Veru Reports Second Quarter Fiscal 2022 Results and Progress of Sabizabulin for COVID-19 Toward a Request for Emergency Use Authorization —FDA States that Veru Should Submit Request for Emergency Use Authorization (EUA) Application Bas |
|
| May 12, 2022 |
As filed with the Securities and Exchange Commission on May 12, 2022 As filed with the Securities and Exchange Commission on May 12, 2022 Registration No. |
|
| May 12, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 1-13602 Veru Inc. (Exac |
|
| May 12, 2022 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Veru Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Title of Securities to be Registered Fee Calculation Rule Amount to be Registered Proposed Maximum Aggregate Offering Price Proposed Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common St |
|
| April 21, 2022 |
VERU / Veru Inc / RA CAPITAL MANAGEMENT, L.P. - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* VERU INC. (Name of Issuer) Common Stock, $0.01 par value per share (Title of Class of Securities) 92536C103 (CUSIP Number) April 11, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to w |
|
| March 31, 2022 |
Exhibit 10.1 VERU INC. 2018 EQUITY INCENTIVE PLAN (as amended and restated effective March 29, 2022) 1 VERU INC. 2018 EQUITY INCENTIVE PLAN 1. Purpose 3 2. Definitions 3 3. Administration 8 4. Shares Subject to Plan 9 5. Eligibility; Per-Participant Limitations 10 6. Specific Terms of Awards 10 7. Certain Provisions Applicable to Awards 16 8. Change of Control 18 9. General Provisions 21 2 VERU IN |
|
| March 31, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 29, 2022 VERU INC. (Exact name of registrant as specified in its charter) Wisconsin 1-13602 39-1144397 (State or other jurisdiction of incorporation) (Commission File Number) (I |
|
| February 10, 2022 |
VERU / Veru Inc / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 1)* Name of issuer: Veru Inc. Title of Class of Securities: Common Stock CUSIP Number: 92536C103 Date of Event Which Requires Filing of this Statement: December 31, 2021 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ??Rule 13d- |
|
| February 9, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 9, 2022 VERU INC. (Exact name of registrant as specified in its charter) Wisconsin 1-13602 39-1144397 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| February 9, 2022 |
Exhibit 99.1 Investor and Media Contact: Samuel Fisch Executive Director, Investor Relations and Corporate Communications Email: [email protected] Veru Reports First Quarter Fiscal 2022 Results as US FC2 Prescription Net Revenues Climb 27% -FC2 Prescription Business Entering 6th Year of Growth ? -FDA Approves Company?s ENTADFI?, New Treatment for Benign Prostatic Hyperplasia with Commerc |
|
| February 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2021 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 1-13602 Veru Inc. (E |
|
| January 28, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the registrant ? Filed by a party other than the registrant ? Check the appropriate box: ?? Preliminary proxy statement ?? Confidential, for use |
|
| January 28, 2022 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the registrant Filed by a party other than the registrant Check the appropriate box: ?? Preliminary proxy statement ?? Confiden |
|
| December 2, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES ?SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended September 30, 2021 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 1-13602 Veru Inc. (Name of |
|
| December 2, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 2, 2021 VERU INC. (Exact name of registrant as specified in its charter) Wisconsin 1-13602 39-1144397 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| December 2, 2021 |
Exhibit 99.1 Investor and Media Contact: Samuel Fisch Executive Director, Investor Relations and Corporate Communications Phone: 800-972-0538 Veru Reports Record Fiscal 2021 Full-Year Financial Results ?FY21 Net Revenues Increase 44% to $61 Million and Gross Profit Increases 56% to $48 Million, Achieving New Historical Highs? ?Phase 3 Sabizabulin COVID-19 Clinical Study for Treatment of Hospitaliz |
|
| December 2, 2021 |
Exhibit 4.3 ? DESCRIPTION OF CAPITAL STOCK ? The following is a summary description of the material terms of the common stock and preferred stock of Veru Inc. (the ?Company,? ?we,? ?us? or ?our?). It may not contain all the information that is important to you. For additional information, you should look at our amended and restated articles of incorporation, as amended, and our amended and restate |
|
| December 2, 2021 |
Exhibit 21 ? Subsidiaries of Veru Inc. (1) ? The subsidiaries of Veru Inc. are as follows: ? ? Name Jurisdiction of Organization ? Aspen Park Pharmaceuticals, Inc. Delaware Badger Acquisition Sub, Inc. Delaware The Female Health Company Limited United Kingdom The Female Health Company (UK) Plc. United Kingdom The Female Health Company (M) SDN.BHD Malaysia ? ? (1)All subsidiaries are wholly owned, |
|
| August 12, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 12, 2021 VERU INC. (Exact name of registrant as specified in its charter) Wisconsin 1-13602 39-1144397 (State or other jurisdiction of incorporation) (Commission File Number) ( |
|
| August 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 1-13602 Veru Inc. (Exact |
|
| August 12, 2021 |
EX-99.1 Exhibit 99.1 Contact: Sam Fisch 800-972-0538 Director of Investor Relations Veru Sets Another Quarterly Record in Both Net Revenues and in Gross Profit for Fiscal 2021 Third Quarter —Q3 FY21 Net Revenues Increase 71% to $18M and Gross Profit Increases 113% to $14M, Achieving New Historical Highs— —Nine-Month FY21 Year to Date Net Revenues Increased 48% to $46M, also a Record High, Even Exc |
|
| May 14, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 10, 2021 VERU INC. (Exact name of registrant as specified in its charter) Wisconsin 1-13602 39-1144397 (State or other jurisdiction of incorporation) (Commission File Number) (IRS |
|
| May 12, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 12, 2021 VERU INC. (Exact name of registrant as specified in its charter) Wisconsin 1-13602 39-1144397 (State or other jurisdiction of incorporation) (Commission File Number) (IRS |
|
| May 12, 2021 |
Exhibit 99.1 Contact: Sam Fisch 800-972-0538 Director of Investor Relations Veru Reports Strong Second-Quarter Financial Results Based on Record High FC2 Prescription Revenues ? First Patient to Be Enrolled this Week in Phase 3 Clinical Trial of Sabizabulin (VERU-111) in High Risk Hospitalized COVID-19 Patients? -New Drug Application Accepted for Review by FDA for Proprietary TADFIN Daily Oral Dos |
|
| May 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ? ? FORM 10-Q ? ? (Mark One) ? ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 ? ? ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to ? Commission File Number 1-136 |
|
| March 26, 2021 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 23, 2021 VERU INC. (Exact name of registrant as specified in its charter) Wisconsin 1-13602 39-1144397 (State or other jurisdiction of incorporation) (Commission File Number) (I |
|
| February 18, 2021 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 17, 2021 VERU INC. (Exact name of registrant as specified in its charter) Wisconsin 1-13602 39-1144397 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| February 18, 2021 |
6,451,613 Shares VERU INC. Common Stock 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-239493 PROSPECTUS SUPPLEMENT (To Prospectus dated July 1, 2020) 6,451,613 Shares VERU INC. Common Stock We are offering 6,451,613 shares of our common stock. Our common stock is listed on the Nasdaq Capital Market under the symbol “VERU.” The last reported sale prices of our common stock on February 5, 2021, February 8, |
|
| February 18, 2021 |
Veru Announces Proposed Public Offering of Common Stock EX-99.1 Exhibit 99.1 Contact: Sam Fisch 800-972-0538 Director of Investor Relations Veru Announces Proposed Public Offering of Common Stock MIAMI – February 17, 2021 – Veru Inc. (NASDAQ: VERU), an oncology biopharmaceutical company with a focus on developing novel medicines for the management of prostate and breast cancer, announced today that it intends to offer and sell, subject to market condit |
|
| February 18, 2021 |
Exhibit 1.1 Execution Version VERU INC. 6,451,613 Shares of Common Stock (par value $0.01 per share) Underwriting Agreement February 17, 2021 JEFFERIES LLC As Representative of the several Underwriters c/o JEFFERIES LLC 520 Madison Avenue New York, New York 10022 Ladies and Gentlemen: Veru Inc., a Wisconsin corporation (the ?Company?), proposes to issue and sell to the several underwriters named i |
|
| February 18, 2021 |
Veru Announces Pricing of Public Offering of Common Stock Exhibit 99.2 Contact: Sam Fisch 800-972-0538 Director of Investor Relations Veru Announces Pricing of Public Offering of Common Stock MIAMI ? February 17, 2021 ? Veru Inc. (NASDAQ: VERU), an oncology biopharmaceutical company with a focus on developing novel medicines for the management of prostate and breast cancer, announced today the pricing of an underwritten public offering of 6,451,613 share |
|
| February 17, 2021 |
424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-239493 The information in this preliminary prospectus supplement is not complete and may be changed. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell these securities and are not soliciting an offer to buy these securities in any jurisdiction where the offer or sale is not p |
|
| February 10, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition - 8-K 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 10, 2021 VERU INC. (Exact name of registrant as specified in its charter) Wisconsin 1-13602 39-1144397 (State or other jurisdiction of incorporation) (Commission File Num |
|
| February 10, 2021 |
EX-99.1 Exhibit 99.1 Contact: Sam Fisch 800-972-0538 Director of Investor Relations Veru Sets Another Quarterly Record in Both Net Revenues and in Gross Profit for Fiscal 2021 First Quarter —Q1 FY21 Net Revenues and Gross Profit of $15M and $11M, Respectively, Achieve New Historical Highs for Second Consecutive Quarter— —Late Clinical Stage Oncology Drug Pipeline Focused on Prostate and Breast Can |
|
| February 10, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2020 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 1- |
|
| February 10, 2021 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 Name of issuer: Veru Inc. Title of Class of Securities: Common Stock CUSIP Number: 92536C103 Date of Event Which Requires Filing of this Statement: December 31, 2020 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Rule 13d-1(b) ☐ Rule 13d-1(c) |
|
| January 28, 2021 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the registrant ☒ Filed by a party other than the registrant ☐ Check the appropriate box: ☐ Preliminary proxy statement ☐ Con |
|
| January 28, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the registrant ☒ Filed by a party other than the registrant ☐ Check the appropriate box: ☐ Preliminary proxy statement ☐ Confidential, for use |
|
| December 10, 2020 |
Exhibit 21 Subsidiaries of Veru Inc. (1) The subsidiaries of Veru Inc. are as follows: Name Jurisdiction of Organization Aspen Park Pharmaceuticals, Inc. Delaware Badger Acquisition Sub, Inc. Delaware The Female Health Company Limited United Kingdom The Female Health Company (UK) Plc. United Kingdom The Female Health Company (M) SDN.BHD Malaysia (1)All subsidiaries are wholly owned, |
|
| December 10, 2020 |
Pro Forma Financial Information. Exhibit 99.1 UNAUDITED PRO FORMA CONSOLIDATED FINANCIAL STATEMENTS On December 8, 2020, the Company entered into an Asset Purchase Agreement (the "Purchase Agreement") with Roman Health Ventures Inc. (the "Purchaser"). Pursuant to, and subject to the terms and conditions of, the Purchase Agreement, the Purchaser purchased substantially all of the assets related to the Company's PREBOOST® busines |
|
| December 10, 2020 |
Exhibit 4.3 DESCRIPTION OF CAPITAL STOCK The following is a summary description of the material terms of the common stock and preferred stock of Veru Inc. (the “Company,” “we,” “us” or “our”). It may not contain all the information that is important to you. For additional information, you should look at our amended and restated articles of incorporation, as amended, and our amended and restate |
|
| December 10, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended September 30, 2020 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 1-13602 Veru Inc. |
|
| December 10, 2020 |
Exhibit 2.2 ASSET PURCHASE AGREEMENT BY AND BETWEEN ROMAN HEALTH VENTURES INC. AND VERU INC. DATED AS OF DECEMBER 8, 2020 TABLE OF CONTENTS 1. Defined Terms; Construction 1 1.01Defined Terms 1 1.02Construction 12 2. Sale of Assets 13 3. Assets Excluded From Transaction 13 4. Excluded Liabilities; Assumption of Liabilities; Non-Assignable Assets 14 4.01Ex |
|
| December 10, 2020 |
Exhibit 10.27 THIRD AMENDMENT TO CREDIT AGREEMENT THIS THIRD AMENDMENT TO CREDIT AGREEMENT (this “Amendment”), dated as of October 5, 2020, is entered into by and among VERU INC., a Wisconsin corporation (“Borrower”), each of the undersigned financial institutions (individually each a “Lender” and collectively “Lenders”) and SWK FUNDING LLC, a Delaware limited liability company, in its capacity |
|
| December 9, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition - 8-K 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 9, 2020 VERU INC. (Exact name of registrant as specified in its charter) Wisconsin 1-13602 39-1144397 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| December 9, 2020 |
EX-99.1 Exhibit 99.1 Contact: Sam Fisch, Director of Investor Relations 800-972-0538 Veru Reports Record Fiscal 2020 Fourth Quarter and Record Full-Year Financial Results —FY20 Full-Year Net Revenues and Gross Profit Achieve Historical Highs of $43 Million and $31 Million, Respectively— — Robust Growing Prescription Sales of FC2 Key Growth Driver; Product Sales Expected to Continue Strong Upward T |
|
| August 13, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 13, 2020 VERU INC. (Exact name of registrant as specified in its charter) Wisconsin 1-13602 39-1144397 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| August 13, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 1-1360 |
|
| August 13, 2020 |
POS AM As filed with the Securities and Exchange Commission on August 13, 2020. Registration Statement No. 333-221120 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 to FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 VERU INC. (Exact Name of Registrant as Specified in Its Charter) Wisconsin 39-1144397 (State or Other Jurisdict |
|
| August 13, 2020 |
VERU INC. $18,900,000 of Common Stock 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-239493 PROSPECTUS SUPPLEMENT (To Prospectus dated July 1, 2020) VERU INC. $18,900,000 of Common Stock Pursuant to this prospectus supplement and the accompanying prospectus, we are offering up to $18,900,000 of shares (the “Purchase Shares”) of our common stock, $0.01 per share, to Aspire Capital Fund, LLC (“Aspire Capit |
|
| August 13, 2020 |
EX-99.1 Exhibit 99.1 Contact: Sam Fisch 800-972-0538 Director of Investor Relations Veru Reports Higher Net Revenues for Fiscal 2020 Third Quarter —Received Agreement and Positive Input from FDA on Phase 3 Pivotal Clinical Trial Design for VERU-111; Phase 3 Trial Expected to Commence in Q1 2021— —VERU-111 Phase 1b Clinical Trial Results Accepted for Presentation at European Society for Medical Onc |
|
| June 30, 2020 |
CORRESP VERU INC. 48 NW 25th Street Suite 102 Miami, Florida 33127 June 30, 2020 SENT VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 Ladies and Gentlemen: Re: Veru Inc. Registration Statement on Form S-3 (File No. 333-239493) In accordance with Rule 461 under the Securities Act of 1933, as amended, on behalf of Veru Inc., the un |
|
| June 26, 2020 |
VERU INC. $23,900,000 of Common Stock plus 212,130 Commitment Shares 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-221120 PROSPECTUS SUPPLEMENT (To Prospectus dated November 14, 2017) VERU INC. $23,900,000 of Common Stock plus 212,130 Commitment Shares Pursuant to this prospectus supplement and the accompanying prospectus, we are offering up to $23,900,000 of shares (the “Purchase Shares”) of our common stock, $0.01 per share, to Asp |
|
| June 26, 2020 |
EX-10.2 Exhibit 10.2 REGISTRATION RIGHTS AGREEMENT REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of June 26, 2020, by and between VERU INC., a Wisconsin corporation (the “Company”), and ASPIRE CAPITAL FUND, LLC, an Illinois limited liability company (together with its permitted assigns, the “Buyer”). Capitalized terms used herein and not otherwise defined herein shall have the respect |
|
| June 26, 2020 |
S-3 As filed with the Securities and Exchange Commission on June 26, 2020. Registration Statement No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 VERU INC. (Exact Name of Registrant as Specified in Its Charter) Wisconsin 39-1144397 (State or Other Jurisdiction of Incorporation or Organization) (I.R.S. |
|
| June 26, 2020 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 26, 2020 VERU INC. (Exact name of registrant as specified in its charter) Wisconsin 1-13602 39-1144397 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| June 26, 2020 |
EX-4.11 Exhibit 4.11 VERU INC. and [ ] as Trustee Guaranteed to the extent set forth therein by the Guarantors named herein. INDENTURE dated as of TABLE OF CONTENTS Page Article 1 DEFINITIONS AND INCORPORATION BY REFERENCE 1 Section 1.01 Certain Definitions 1 Section 1.02 Other Definitions 3 Section 1.03 Incorporation by Reference of Trust Indenture Act 4 Section 1.04 Rules of Construction 4 Artic |
|
| June 26, 2020 |
EX-10.1 Exhibit 10.1 COMMON STOCK PURCHASE AGREEMENT COMMON STOCK PURCHASE AGREEMENT (the “Agreement”), dated as of June 26, 2020 by and between VERU INC., a Wisconsin corporation (the “Company”), and ASPIRE CAPITAL FUND, LLC, an Illinois limited liability company (the “Buyer”). Capitalized terms used herein and not otherwise defined herein are defined in Section 10 hereof. WHEREAS: Subject to the |
|
| May 13, 2020 |
As filed with the Securities and Exchange Commission on May 13, 2020 Registration No. |
|
| May 13, 2020 |
Exhibit 10.3 VERU INC. NON-QUALIFIED STOCK OPTION GRANT AGREEMENT Pursuant to the stock option grant notice (the “Notice”) which is delivered concurrently with this stock option agreement (this “Agreement”), Veru Inc., a Wisconsin corporation (the “Company”), has granted to Optionee an Option under the Company’s 2017 Equity Incentive Plan (the “Plan”) to purchase the number of Shares indicated |
|
| May 13, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 1-136 |
|
| May 13, 2020 |
Exhibit 10.2 VERU INC. NON-QUALIFIED STOCK OPTION GRANT AGREEMENT Pursuant to the stock option grant notice (the “Notice”) which is delivered concurrently with this stock option agreement (this “Agreement”), Veru Inc., a Wisconsin corporation (the “Company”), has granted to Optionee an Option under the Company’s 2018 Equity Incentive Plan (the “Plan”) to purchase the number of Shares indicated |
|
| May 13, 2020 |
EX-99.1 Exhibit 99.1 Contact: Sam Fisch 800-972-0538 Veru Reports Strong Fiscal 2020 Second Quarter Results as Net Revenues Increase 43%, Gross Profit Up 61% —Strong Clinical Progress in Advanced Prostate Cancer: VERU-111 Demonstrates Safety and Evidence of Antitumor Activity with Durable PSA Declines and Tumor Regression in Phase 1b Study; Phase 2 study enrolling; Plan to Meet with FDA as Positiv |
|
| May 13, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 13, 2020 VERU INC. (Exact name of registrant as specified in its charter) Wisconsin 1-13602 39-1144397 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| March 26, 2020 |
Exhibit 10.1 VERU INC. 2018 EQUITY INCENTIVE PLAN (as amended and restated effective March 24, 2020) 1 VERU INC. 2018 EQUITY INCENTIVE PLAN Page 1 Purpose 3 2 Definitions 3 3 Administration 8 4 Shares Subject to Plan 9 5 Eligibility; Per‑Participant Limitations 10 6 Specific Terms of Awards 10 7 Certain Provisions Applicable to Awards 16 8 Change of Control 18 9 General Provisions 21 2 V |
|
| March 26, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 24, 2020 VERU INC. (Exact name of registrant as specified in its charter) Wisconsin 1-13602 39-1144397 (State or other jurisdiction of incorporation) (Commission File |
|
| February 12, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2019 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 1- |
|
| February 12, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 12, 2020 VERU INC. (Exact name of registrant as specified in its charter) Wisconsin 1-13602 39-1144397 (State or other jurisdiction of incorporation) (Commission File Num |
|
| February 12, 2020 |
EX-99.1 Exhibit 99.1 Contact: Sam Fisch 800-972-0538 Veru Continues Strong Positive Sales Momentum in Fiscal 2020 First Quarter; Net Revenues Increase 66%, Gross Profit Up 57% — Completion of VERU-111 Phase 1b Clinical Trial and Initiation of Phase 2 Prostate Cancer Clinical Trial in Q2 FY 2020 — — Zuclomiphene Expected to Enter Pivotal Phase 3 Clinical Trial for Treating Hot Flashes in Men with P |
|
| February 11, 2020 |
FHCO / VERU INC. DEFA14A - - DEFA14A DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the registrant ☒ Filed by a party other than the registrant ☐ Check the appropriate box: ☐ Preliminary proxy statement ☐ Confidential, fo |
|
| January 28, 2020 |
FHCO / VERU INC. DEFA14A - - DEFA14A DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the registrant ☒ Filed by a party other than the registrant ☐ Check the appropriate box: ☐ Preliminary proxy statement ☐ Confidential, fo |
|
| January 28, 2020 |
FHCO / VERU INC. DEF 14A - - DEF 14A DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| December 12, 2019 |
Exhibit 4.3 DESCRIPTION OF CAPITAL STOCK The following is a summary description of the material terms of the common stock and preferred stock of Veru Inc. (the “Company,” “we,” “us” or “our”). It may not contain all the information that is important to you. For additional information, you should look at our amended and restated articles of incorporation, as amended, and our amended and restate |
|
| December 12, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended September 30, 2019 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 1-13602 Veru |
|
| December 12, 2019 |
Veru Reports Fiscal 2019 Full-Year Net Revenues Doubled, Gross Profit Up 147% EX-99.1 Exhibit 99.1 Contact: Sam Fisch 800-972-0538 Veru Reports Fiscal 2019 Full-Year Net Revenues Doubled, Gross Profit Up 147% —Update on Ongoing Phase 1b/2 VERU-111, Oral Selective Antitubulin, Clinical Trial Demonstrates Antitumor Activity and No Dose Related Toxicity Reached in Men with Metastatic Castration Resistant Prostate Cancer— —VERU-111 Has Promising Signs of Progression Free Surviv |
|
| December 12, 2019 |
Financial Statements and Exhibits, Results of Operations and Financial Condition Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 12, 2019 VERU INC. (Exact name of registrant as specified in its charter) Wisconsin 1-13602 39-1144397 (State or other jurisdiction of incorporation) (Commission Fil |
|
| December 12, 2019 |
Exhibit 21 Subsidiaries of Veru Inc. (1) The subsidiaries of Veru Inc. are as follows: Name Jurisdiction of Organization Aspen Park Pharmaceuticals, Inc. Delaware Badger Acquisition Sub, Inc. Delaware The Female Health Company Limited United Kingdom The Female Health Company (UK) Plc. United Kingdom The Female Health Company (M) SDN.BHD Malaysia (1)All subsidiaries are wholly owned, |
|
| August 8, 2019 |
Financial Statements and Exhibits, Results of Operations and Financial Condition Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2019 VERU INC. (Exact name of registrant as specified in its charter) Wisconsin 1-13602 39-1144397 (State or other jurisdiction of incorporation) (Commission File N |
|
| August 8, 2019 |
EX-99.1 Exhibit 99.1 Contact: Sam Fisch 800-972-0538 Veru Reports Higher Net Revenues and Gross Profit for its Fiscal 2019 Third Quarter Promising Clinical Observations for Both Advancing VERU-111 and Zuclomiphene Prostate Cancer Clinical Trials — — Added VERU-100, Novel First GnRH Antagonist 3 Month Depot Formulation for Androgen Deprivation — — Had Successful PreNDA meeting with FDA for TADFIN f |
|
| August 8, 2019 |
FHCO / VERU INC. 10-Q - Quarterly Report - 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2019 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 1-1360 |
|
| May 15, 2019 |
EX-99.1 Exhibit 99.1 Contact: Sam Fisch 800-972-0538 Veru Reports Strong Fiscal 2019 Second-Quarter Financial Results — Prostate Cancer Clinical Trials Advancing; Early Clinical Observations Look Promising — — Strong Financial Results for Q2 and YTD FY 2019 — — Company to Host Investor Conference Call on Wednesday, May 15, 2019, 8 a.m. ET — MIAMI — May 15, 2019 — Veru Inc. (NASDAQ: VERU) an oncolo |
|
| May 15, 2019 |
Financial Statements and Exhibits, Results of Operations and Financial Condition Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 15, 2019 VERU INC. (Exact name of registrant as specified in its charter) Wisconsin 1-13602 39-1144397 (State or other jurisdiction of incorporation) (Commission File Num |
|
| May 15, 2019 |
FHCO / VERU INC. 10-Q Quarterly Report 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2019 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 1-136 |
|
| May 15, 2019 |
Exhibit 10.1 SEPARATION AGREEMENT AND GENERAL RELEASE THIS SEPARATION AGREEMENT AND GENERAL RELEASE ("Agreement") is between Veru Inc. ("Company") and Charles T. Todd, Jr. ("Employee"). RECITALS The Company and Employee desire to effect a final resolution and settlement of all matters and issues relating directly or indirectly to Employee's employment with the Company and Employee's March 27 |
|
| May 15, 2019 |
Exhibit 10.3 SECOND AMENDMENT TO CREDIT AGREEMENT & AMENDMENT TO RESIDUAL ROYALTY AGREEMENT THIS SECOND AMENDMENT TO CREDIT AGREEMENT AND AMENDMENT TO RESIDUAL ROYALTY AGREEMENT (this “Amendment”), dated as of May 13, 2019, is entered into by and among VERU INC., a Wisconsin corporation (“Borrower”), each of the undersigned financial institutions (individually each a “Lender” and collectively |
|
| May 15, 2019 |
Form S-8 As filed with the Securities and Exchange Commission on May 15, 2019 Registration No. |
|
| March 29, 2019 |
EX-3.1 Exhibit 3.1 ARTICLES OF AMENDMENT TO THE AMENDED AND RESTATED ARTICLES OF INCORPORATION OF VERU INC. 1. The name of the Corporation is Veru Inc. 2. The amendment adopted relates to Article V of the Amended and Restated Articles of Incorporation. The first portion of Article V is amended to read as follows: ARTICLE V The aggregate number of shares which the Corporation shall have the authori |
|
| March 29, 2019 |
EX-10.1 Exhibit 10.1 VERU INC. 2018 EQUITY INCENTIVE PLAN (as amended and restated effective March 26, 2019) VERU INC. 2018 EQUITY INCENTIVE PLAN 1. Purpose 1 2. Definitions 1 3. Administration 6 4. Shares Subject to Plan 7 5. Eligibility; Per-Participant Limitations 8 6. Specific Terms of Awards 8 7. Certain Provisions Applicable to Awards 14 8. Change of Control 16 9. General Provisions 19 VERU |
|
| March 29, 2019 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 26, 2019 VERU INC. (Exact name of registrant as specified in its charter) Wisconsin 1-13602 39-1144397 (State or other jurisdiction of incorporation) (Commission File N |
|
| February 13, 2019 |
EX-99.1 Exhibit 99.1 Contact: Kevin Gilbert 786-322-2213 Veru Reports Strong Fiscal 2019 First Quarter Financial Results — Drug Development Advancing: Successful TADFIN Clinical Trial with NDA Filing in 2019; Two Prostate Cancer Clinical Trials Enrolling — — Company to Host Investor Conference Call on Wednesday, February 13, 2019, 8 a.m. ET – MIAMI — February 13, 2019 — Veru Inc. (NASDAQ: VERU), a |
|
| February 13, 2019 |
Financial Statements and Exhibits, Results of Operations and Financial Condition Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 13, 2019 VERU INC. (Exact name of registrant as specified in its charter) Wisconsin 1-13602 39-1144397 (State or other jurisdiction of incorporation) (Commission Fil |
